Equities research analysts predict that Global Blood Therapeutics Inc (NASDAQ:GBT) will post earnings per share of ($1.19) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Global Blood Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.30) and the highest estimate coming in at ($1.13). Global Blood Therapeutics posted earnings of ($0.93) per share in the same quarter last year, which indicates a negative year over year growth rate of 28%. The business is expected to report its next quarterly earnings results on Wednesday, February 26th.
On average, analysts expect that Global Blood Therapeutics will report full year earnings of ($4.16) per share for the current year, with EPS estimates ranging from ($4.27) to ($4.09). For the next year, analysts expect that the firm will report earnings of ($4.61) per share, with EPS estimates ranging from ($5.57) to ($4.02). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Global Blood Therapeutics.
Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.03) by ($0.04). During the same period in the previous year, the business posted ($0.83) EPS.
Several research firms recently issued reports on GBT. Wedbush restated a “buy” rating and issued a $143.00 price target on shares of Global Blood Therapeutics in a research note on Tuesday, November 26th. Cantor Fitzgerald reissued a “buy” rating and set a $98.00 target price (down previously from $110.00) on shares of Global Blood Therapeutics in a report on Monday, November 25th. HC Wainwright reissued a “buy” rating and issued a $150.00 target price on shares of Global Blood Therapeutics in a research report on Wednesday, October 9th. Morgan Stanley set a $60.00 price target on shares of Global Blood Therapeutics and gave the company a “hold” rating in a research note on Friday, August 9th. Finally, Nomura raised their price target on shares of Global Blood Therapeutics from $109.00 to $112.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $91.44.
Shares of Global Blood Therapeutics stock traded up $0.44 on Wednesday, hitting $72.93. The stock had a trading volume of 68,652 shares, compared to its average volume of 1,331,700. The stock has a market cap of $4.01 billion, a price-to-earnings ratio of -21.39 and a beta of 1.70. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.04. Global Blood Therapeutics has a twelve month low of $34.92 and a twelve month high of $73.23. The business’s 50 day moving average is $53.03 and its two-hundred day moving average is $53.44.
In other Global Blood Therapeutics news, insider Lesley Ann Calhoun sold 2,765 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $54.36, for a total transaction of $150,305.40. Following the completion of the transaction, the insider now directly owns 887 shares in the company, valued at $48,217.32. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Tricia Borga Suvari sold 3,434 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $66.74, for a total value of $229,185.16. Following the transaction, the insider now directly owns 6,752 shares of the company’s stock, valued at approximately $450,628.48. The disclosure for this sale can be found here. Insiders have sold 36,616 shares of company stock worth $2,096,540 over the last quarter. Corporate insiders own 4.30% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in GBT. Quest Capital Management Inc. ADV acquired a new position in Global Blood Therapeutics during the third quarter worth about $26,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of Global Blood Therapeutics in the 2nd quarter valued at approximately $27,000. Lindbrook Capital LLC boosted its stake in shares of Global Blood Therapeutics by 133.3% in the 3rd quarter. Lindbrook Capital LLC now owns 700 shares of the company’s stock valued at $34,000 after purchasing an additional 400 shares in the last quarter. Captrust Financial Advisors acquired a new stake in shares of Global Blood Therapeutics in the 2nd quarter valued at approximately $42,000. Finally, Truvestments Capital LLC grew its holdings in shares of Global Blood Therapeutics by 48.0% during the 3rd quarter. Truvestments Capital LLC now owns 925 shares of the company’s stock valued at $45,000 after purchasing an additional 300 shares during the last quarter. 98.78% of the stock is currently owned by institutional investors and hedge funds.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Further Reading: What is the Russell 2000 Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.